MEI Pharma, Inc. 8-K 2009
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 19, 2009
Marshall Edwards, Inc.
(Exact name of registrant as specified in its charter)
140 Wicks Road, North Ryde, NSW, 2113 Australia
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code: (011) 61 2 8877-6196
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
TABLE OF CONTENTS
Effective March 19, 2009, William D. Rueckert resigned as a member of the Board of Directors of Marshall Edwards, Inc. (the Company). Mr. Rueckert was the Chairman of the Audit Committee and the audit committee financial expert as defined by Item 407(d)(5) of Regulation S-K.
Simultaneous with Mr. Rueckerts resignation, the Board of Directors appointed Leah Cann as a member of the Board of Directors and Chairperson of the Audit Committee effective immediately. The Board of Directors has determined that Ms. Cann qualifies as an audit committee financial expert as defined in Item 407(d)(5) of Regulation S-K.
The Company issued a press release on March 19, 2009 announcing Mr. Rueckerts resignation from, and Ms. Canns appointment to, the Board of Directors. A copy of the press release is attached to this Form 8-K as Exhibit 99.1
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 24, 2009